The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

The Victorian Government is investing $1.7 million into six new mRNA research projects aimed at accelerating breakthroughs.

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen, with a price target of $146.00. The company’s shares opened today at $132.99. E ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen today and set a price target of $330.00. The company’s shares opened today at $298.51. Elevate Your Invest ...

RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and ...

In June, family offices made 60 direct investments in companies, ending three straight months of declining deal activity, ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...